Table 3.
Amounts of HEPES in different 68Ga-radiopharmaceuticals obtained from different institutes and analyzed by the HPLC method (n = the number of samples from different batches)
| [68Ga]Ga-DOTATOC | |||
|---|---|---|---|
| HEPES (μg/mL) |
Maximum amount in VInj (μg) a | Maximum VInj (mL) |
|
| Institute A (n = 3) | 21 ± 4 | 171 ± 35 | 10 ± 2 |
| Institute B (n = 6) | 19 ± 8 | 150 ± 60 | 11 ± 1 |
| Institute C | ____ | ____ | ____ |
| [68Ga]Ga-PSMA-11 | |||
| Institute A (n = 3) | 7 ± 10 | 58 ± 81 | 14 ± 3b |
| Institute B (n = 5) | 8 ± 7 | 64 ± 54 | 16 ± 3b |
| Institute C | ____ | ____ | ____ |
| [68Ga]Ga-NODAGA-Exendin | |||
| Institute A (n = 3) | 31 ± 1§ | 291 ± 39 | 6 ± 1 |
| Institute B (n = 3) | 36 ± 5§ | 245 ± 12 | 6 ± 1 |
| Institute C (n = 3) | 60 ± 8* | 482 ± 69 | 2 ± 1 |
a When considering the recommended volume of injection of 8 mL. b When the amounts of HEPES were below LOQ, the total volume of the radiopharmaceutical (VT = 16 mL) was considered the maximum injected volume. §p < 0.05 when comparing the HEPES concentration present in different radiopharmaceuticals obtained from the same institute.* p < 0.05 when comparing the HEPES concentration present in the same radiopharmaceutical obtained in different institutes